Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 25Carcinoma, Renal Cell 22Lung Neoplasms 11Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Colorectal Neoplasms 9Prostatic Neoplasms 8Hodgkin Disease 8Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Adenocarcinoma Of Esophagus 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Nasopharyngeal Carcinoma 4Multiple Myeloma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Basal Cell 4Brain Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Sarcoma, Kaposi 3Recurrence 3

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Nivolumab × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡